Drug Discovery Pipeline

Applying our cellular reprogramming platform to therapeutic discovery.

Home 9 Drug Discovery Pipeline

Pipeline Overview

LIVIUS is advancing a therapeutic drug discovery pipeline built on its proprietary cellular reprogramming platform.

By applying miRNA-driven biology, small-molecule epigenetic control, and DNA repair mechanisms, we are developing candidates that target the underlying drivers of disease progression. Our pipeline is designed to expand across multiple indications while maintaining a consistent scientific foundation.

Therapeutic Focus Areas

Z

Cellular Rejuvenation & Regenerative Medicine

Our lead therapeutic programs focus on restoring cellular function through controlled reprogramming.

These efforts explore applications in conditions associated with cellular aging, degeneration, and functional decline, where current treatment options remain limited.

Z

Tissue-Specific Therapeutics

In parallel, LIVIUS is advancing tissue-targeted therapeutic programs that leverage the platform’s adaptability.

By tailoring delivery and molecular control to specific tissues, we aim to explore treatments for localized degenerative and inflammatory conditions.

Z

Genomic Stability–Oriented Therapeutics

Building on evidence of DNA damage repair occurring alongside cellular reprogramming, LIVIUS is exploring therapeutic concepts centered on restoring genomic integrity.

These programs represent an emerging area of research with potential relevance to diseases driven by accumulated genetic damage.

Development Stage

LIVIUS’s therapeutic programs are currently in early discovery and preclinical research stages.

Progression through development is guided by scientific validation, translational feasibility, and regulatory alignment.

Z

Early discovery and target validation

At this stage, we focus on identifying and validating biological targets through platform-driven insights.
By leveraging cellular reprogramming, miRNA biology, and epigenetic control, we assess target relevance, mechanism consistency, and biological response at the cellular level.
Z

Preclinical research and proof-of-concept generation

Building on validated targets, our preclinical efforts aim to generate proof-of-concept data that demonstrate reproducible biological effects.
These studies are designed to support translational readiness while informing future development strategies.

Our drug discovery efforts are supported by real-world validation through commercial applications and ongoing research initiatives.

Explore Commercialized Products